Germany-based Synlab, a leading medical diagnostic services and specialty testing group in Europe, is selling its activities in Slovakia to Unilabs Group, a leading European provider of laboratory, pathology and imaging services in medical diagnostics in Europe.
The acquisition is expected to support Unilabs‘ commitment to provide high-quality medical diagnostics in Slovakia.
“We have a highly skilled and dedicated Unilabs team in Slovakia who provide clarity, reassurance and insights to patients and their clinicians,” said Badhri Srinivasan, group CEO of Unilabs. “We look forward to welcoming the new teams into Unilabs Slovakia.”
Unilab operates laboratory and medical diagnostic imaging facilities in 14 countries: Czech Republic, Denmark, Finland, France, Italy, Norway, Peru, Portugal, Slovakia, Spain, Sweden, Switzerland, UAE, and the UK.
Strategic focus
The agreed divestment aligns with Synlab’s strategy to densify its network by focusing on countries that offer attractive perspectives for further development.
“Efficient capital deployment is a key element of our group strategy. Through active portfolio management, we continuously review our activities, the strategic perspectives and future growth potential across our markets,” said Mathieu Floreani, CEO of the Synlab Group. “We have agreed to sell our operations in Slovakia, as we see limited opportunities to further scale up.”
Synlab offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments, and corporates. It operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy.
Operations in Slovakia accounted for approximately 0.7% of total Synlab revenue in 2025. In April 2025, Sweden-headquartered international diagnostic services company Medicover acquired Synlab’s local businesses in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia for €71.3m. In 2024, Eurofins acquired Synlab’s clinical diagnostics operations in Spain, and Affidea acquired Synlab Lithuania and in 2023, Synlab sold its Swiss laboratory network for CHF100m to Sonic.
Synlab went public in 2021, selling shares at €18 per share, before Cinven took it private again, paying €10 per share for the remaining stock it did not already hold. In 2024, Cinven was joined by US-based Labcorp as a strategic minority investor in the group.
Synlab was advised by CMS (Dr Christoph Lächler, Daniel Mahn, Martina Gavalec)
Dr Peter Macheiner acted as Synlab in-house lawyer.
Press release: SYNLAB to further densify its network
